How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

365 results for

Intraocular Carbonic Anhydrase Inhibitor

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

361. Effect of a topical carbonic anhydrase inhibitor, 6-hydroxybenzo[b]thiophene-2-sulfonamide, on intraocular pressure in normotensive subjects. (PubMed)

Effect of a topical carbonic anhydrase inhibitor, 6-hydroxybenzo[b]thiophene-2-sulfonamide, on intraocular pressure in normotensive subjects. A prospective randomized clinical trial was carried out to determine the efficacy of 6-hydroxybenzo[b]thiophene-2-sulfonamide, a potent new carbonic anhydrase inhibitor, in lowering intraocular pressure (IOP) in normotensive volunteers. The drug was administered as a 2% suspension twice daily for 1 week to one eye in 10 subjects. Ten other subjects

1987 Canadian journal of ophthalmology. Journal canadien d'ophtalmologie Controlled trial quality: uncertain

362. [Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine]. (PubMed)

[Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine]. We studied the effect of a single dose of the local carbonic anhydrase inhibitor, MK-927, on lowering IOP in 24 patients with bilateral primary open-angle glaucoma or ocular hypertension and compared it with the effect of pilocarpin in 9 patients. Following a washout of any glaucoma medication of 3 to 14 days, a diurnal IOP curve (...) , the mean reduction of the maximal IOP treated with pilocarpin was 7.3 mmHg (25.8%) and 10.2 mmHg (34.2%) following MK-927. Considering the IOP lowering of MK-927 shown here, the possibility of a topically effective glaucoma therapy by local carbonic anhydrase inhibitor seems to be established. The IOP lowering effect of MK-927 appears to be similar to that of pilocarpin 1%.

1990 Fortschritte der Ophthalmologie : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft Controlled trial quality: uncertain

363. Intraocular pressure effects of carbonic anhydrase inhibitors in primary open-angle glaucoma. (PubMed)

Intraocular pressure effects of carbonic anhydrase inhibitors in primary open-angle glaucoma. We tested the effect on intraocular pressure of three commonly used oral carbonic anhydrase inhibitor preparations in a controlled, randomized, comparative study on patients with primary open-angle glaucoma. Preparations tested included acetazolamide tablets, acetazolamide Sequels, and methazolamide tablets. The effect of the three carbonic anhydrase inhibitors was assessed by using a statistical (...) modeling approach as well as by evaluating the average maximum reduction in intraocular pressure for each preparation. Dosage and time effects were also determined. As expected, each drug preparation was more effective in reducing intraocular pressure when administered to a patient who had already been treated with the carbonic anhydrase inhibitor preparation. The amount of intraocular pressure lowering was directly related to dose for both acetazolamide preparations. Of particular interest

1989 American journal of ophthalmology Controlled trial quality: uncertain

364. Comparative effects of intraocular pressure between systemic and topical carbonic anhydrase inhibitors: a clinical masked, cross-over study. (PubMed)

Comparative effects of intraocular pressure between systemic and topical carbonic anhydrase inhibitors: a clinical masked, cross-over study. The aims of the following study were to compare the efficacy of Dorzolamide 1% eye drops with systemic Acetazolamide on the ocular pressure diurnal curve in patients with maximal medical therapy. Three ocular pressure curve were performed in glaucomatous patients, already receiving maximal medical therapy. After a baseline curve, patients were pretreated (...) either with Dorzolamide 1% eye drops or 250 mg Acetazolamide tablets in a double-blind cross-over study. Dorzolamide 1% eye drops and 250 mg Acetazolamide tablets significantly reduced intraocular pressure (IOP) at 2 and 4 h after pretreatment. Both treatments caused a significantly additional decrease of IOP despite maximal medical therapy. Dorzolamide 1% eye drops is as effective as Acetazolamide tablets in reducing the IOP curve. Topical carbonic anhydrase inhibitors may represent an additional

1997 Pharmacological research : the official journal of the Italian Pharmacological Society Controlled trial quality: uncertain

365. [Postoperative behavior of intraocular pressure after posterior Nd:YAG laser capsulotomy--critical evaluation in preventive administration of local carbonic anhydrase II inhibitor dorzolamide hydrochloride (Trusopt)]. (PubMed)

[Postoperative behavior of intraocular pressure after posterior Nd:YAG laser capsulotomy--critical evaluation in preventive administration of local carbonic anhydrase II inhibitor dorzolamide hydrochloride (Trusopt)]. The aim of the present study was to examine the influence of the topical carbonic anhydrase-II-inhibitor dorzolamide hydrochloride (Trusopt) in regarding to behaviour of intraocular eyepressure after Nd:YAG-laser-capsulotomy.The study was carried out as a double-blind-test (...) . In a period of nine months, 120 patients underwent Nd:YAG-laser-capsulotomy. One group was given dorzolamide hydrochloride (Trusopt), the other group (placebo) remained without medication. The intraocular pressure was measured before capsulotomy and four hours post-op. For statistical evaluation the t-test of not-associated spot-checks was performed.The prophylactic use of the topical carbonic anhydrase-II-inhibitor dorzolamide hydrochloride (Trusopt) after nd:YAG-laser-capsulotomy shows a highly

1998 Klinische Monatsblatter fur Augenheilkunde Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>